Related Experiment Video
Updated: Jul 18, 2026
07:40
Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
Published on: January 12, 2022
4.8K
A Case Report of Fedratinib-Associated Uveitis
William Evans1, Christina Mathew1, James Richardson-May1
1Ophthalmology, Salisbury District Hospital, Salisbury, GBR.
Cureus
|February 16, 2024
Summary
Drug-induced uveitis is a rare complication, especially with new medications. This case highlights fedratinib as a potential cause of hypopyon uveitis, emphasizing diagnostic challenges and management strategies.
Area of Science:
- Ophthalmology
- Pharmacology
Background:
- Drug-induced uveitis is an uncommon but significant adverse effect associated with various medications.
- Accurate diagnosis necessitates a high index of suspicion, comprehensive patient history, clinical examination, and targeted investigations.
Observation:
- A 64-year-old male with myelofibrosis developed hypopyon uveitis after initiating fedratinib therapy.
- The patient presented with characteristic uveitis symptoms, and other potential causes were systematically excluded through a thorough diagnostic workup.
Findings:
- A temporal relationship was established between the initiation of fedratinib and the onset of hypopyon uveitis.
- Literature review revealed no previously reported cases of uveitis associated with fedratinib, indicating this may be a novel adverse drug reaction.
Implications:
- This case underscores the importance of considering drug-induced uveitis in patients presenting with new-onset uveitis, particularly those on novel therapeutics like fedratinib.
- Despite the inability to discontinue fedratinib, close monitoring and collaborative management with steroids led to the patient's recovery, highlighting effective strategies for managing this rare condition.
